Programs Overview
Affinium Pharmaceuticals is developing novel, specific-spectrum antibacterial therapeutics that inhibit the bacterial fatty acid synthesis pathway (FASII), an unexploited therapeutic target. Affinium specializes in structure-guided inhibition of the FabI enzyme that represents a key step in the FASII cycle, which is essential for bacterial growth and survival.
The seed assets of the Affinium FabI program were purchased from GlaxoSmithKline in December 2002. Affinium utilized its structure-guided drug discovery platform to synthesize hundreds of new compounds to further optimize staphylococcal-specific inhibitors, and to also identify compounds that inhibit other key pathogens including E. coli, F. tularensis, H. pylori, P. acnes and M. tuberculosis
AFN-1252 was selected from the staphylococcal FabI program as the lead clinical candidate, and it is currently in oral Phase 1 trials. AFN-1252 is a highly potent, specific spectrum agent that is active mainly against staphylococci, with little to no activity against other common bacterial species and gut flora. By not disrupting the human microbiome, AFN-1252 has a potentially significant safety advantage, with much reduced antibiotic associated adverse events such as diarrhea, colitis, candidiasis and C. difficile infections. AFN-1252 has a very low propensity for resistance development, and has shown excellent oral efficacy in multiple animal models of infection. AFN-1252 is protected by a global patent portfolio through at least 2022.
For out-licensing information please contact Leisa Dennehy at ldennehy@afnm.com
Duo an num quam fuisset sadipscing, elit animal doc endi enum num ut.